Takeda

ADCETRIS
Homepage

ADCETRIS Reimbursement Status

Takeda
Takeda

ADCETRIS Resources and Videos

ADCETRIS prescribing information and adverse event reporting

ADCETRIS (brentuximab vedotin) has received a conditional marketing authorisation in Europe 

Takeda

C-APROM/UKI/ADCE/0020   November 2020

References
1ADCETRIS Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2859/smpc

This virtual stand was produced and fully funded by Takeda UK Ltd and is intended for healthcare professionals only.

© Takeda UK Limited, 2020. Registered office: 1 Kingdom Street, London, W2 6BD, United Kingdom. Registered in England and Wales No. 3362860